KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other financing activities (2018 - 2022)

Historic Other financing activities for Sarepta Therapeutics (SRPT) over the last 8 years, with Q4 2022 value amounting to $554000.0.

  • Sarepta Therapeutics' Other financing activities fell 6131.28% to $554000.0 in Q4 2022 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year decrease of 4189.58%. This contributed to the annual value of $716000.0 for FY2022, which is 5000.0% down from last year.
  • Sarepta Therapeutics' Other financing activities amounted to $554000.0 in Q4 2022, which was down 6131.28% from $1.4 million recorded in Q4 2021.
  • Over the past 5 years, Sarepta Therapeutics' Other financing activities peaked at $5.8 million during Q2 2018, and registered a low of $554000.0 during Q4 2022.
  • For the 4-year period, Sarepta Therapeutics' Other financing activities averaged around $2.4 million, with its median value being $1.4 million (2021).
  • In the last 5 years, Sarepta Therapeutics' Other financing activities surged by 438.99% in 2019 and then crashed by 6131.28% in 2022.
  • Sarepta Therapeutics' Other financing activities (Quarter) stood at $3.3 million in 2018, then rose by 4.39% to $3.4 million in 2019, then tumbled by 58.47% to $1.4 million in 2021, then crashed by 61.31% to $554000.0 in 2022.
  • Its Other financing activities stands at $554000.0 for Q4 2022, versus $1.4 million for Q4 2021 and $1.4 million for Q2 2021.